Today's Rundown GBT touts positive sickle cell trial, but shares yo-yo as investors mull data FDA panel rejects Pain Therapeutics’ abuse-deterrent opioid Remoxy AbbVie powers CAR-macrophage startup Carisma to $53M A round [Sponsored] The Growing Need for Data Management Solutions in Clinical Labs Summit dumps ezutromid after phase 2 Duchenne fail Aquinox to halt work on inflammatory pain drug rosiptor after phase 3 trial failure EMA demands more data from Amicus, denting stock Arcus, Infinity team up on triple-combination studies in TNBC and ovarian cancer GE to spin off health unit to form medtech giant Featured Story | | | Wednesday, June 27, 2018 Global Blood Therapeutics saw its shares dip and climb this morning as those plugging the positive fought it out with those questioning how good its data really are, and whether it can achieve its new goal of a swift approval. |
|
|
Top Stories Tuesday, June 26, 2018 An FDA panel voted 14-3 against the approval of Remoxy ER, Pain Therapeutics' extended-release, capsule gel form of the opioid oxycodone. Wednesday, June 27, 2018 Carisma Therapeutics has raised $53 million to take its lead CAR-macrophage candidate into human testing. The University of Pennsylvania spinout plans to equip macrophages to identify and gobble up solid tumor cells by combining them with chimeric antigen receptors (CARs). Monday, June 25, 2018 The increasing demand for innovation in research and the related pressures to deliver on the most promising findings from discovery are also driving the need for simultaneous innovation in the technologies that enable that innovation and, likewise, the reliance on data management solutions that respond to an increasingly complex scientific environment. Wednesday, June 27, 2018 Despite posting promising early data, Summit Therapeutics' Duchenne muscular dystrophy drug missed its primary and secondary endpoints in a phase 2 trial, leading the biotech to drop the program. Wednesday, June 27, 2018 Aquinox Pharmaceuticals is abandoning development of its lead drug candidate, rosiptor, after it was unable to beat placebo in a phase 3 clinical trial in chronic bladder pain. The disappointing topline results come less than two months after Astellas agreed to purchase R&D rights to the drug in several Asia-Pacific countries for $25 million upfront. Wednesday, June 27, 2018 The EMA has told Amicus Therapeutics it lacks the data to file for conditional approval of its Pompe disease drug in Europe. Amicus needs to gather data on more patients and track the progress of previously treated people before seeking conditional approval, delaying the filing to 2019 or beyond. Tuesday, June 26, 2018 Arcus Biosciences and Infinity Pharmaceuticals are teaming up to evaluate their lead oncology programs in triple-combination immunotherapy studies, testing two regimens in both triple-negative breast cancer and ovarian cancer. Wednesday, June 27, 2018 GE is set to spin off its healthcare unit into a standalone company. The action will create one of the largest healthcare businesses in the world, with products spanning medical imaging, data analytics and patient monitoring. Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Blue Latitude Health Blue Latitude Health explores the commercial barriers and new stakeholder connections for pharma companies developing precision medicines, and reveals how to grasp novel opportunities in the new era of healthcare. Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Innovation, Collaboration and Entrepreneurship in Drug Discovery June 28, 2018 | Cambridge, UK Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA RESI HealthTech Week September 5-7, 2018 | Boston, MA The 16th Annual Discovery on Target September 25-28, 2018 | Boston, MA FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA 10th International Leaders in Biobanking Congress October 14-16, 2018 | Cleveland, OH Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation | 